Among the most studied SST2 antagonists is [177Lu]Lu-OPS201, also denoted as 177Lu-satoreotide tetraxetan or [177Lu]Lu-DOTA-JR11 (where JR11 is 4-Cl-Phe-cyclo[dCys-Aph(Hor)-dAph(Cbm)-Lys-Thr-Cys]-dTyr-NH2), which was associated with a significantly higher and longer tumour accumulation in vivo as well as a higher DNA double strand breakage in SST2-expressing tumours when compared to the agonist [177Lu]Lu-DOTA-TATE [5,7,9,10]. This evidence concerns the gene SSTR2 and neoplasm.